针对多种肿瘤抗原的新型合成DNA疫苗对前列腺癌的免疫治疗

Q2 Biochemistry, Genetics and Molecular Biology
Devivasha Bordoloi, Peng Xiao, Hyeree Choi, Michelle Ho, Alfredo Perales-Puchalt, Makan Khoshnejad, J Joseph Kim, Laurent Humeau, Alagarsamy Srinivasan, David B Weiner, Kar Muthumani
{"title":"针对多种肿瘤抗原的新型合成DNA疫苗对前列腺癌的免疫治疗","authors":"Devivasha Bordoloi,&nbsp;Peng Xiao,&nbsp;Hyeree Choi,&nbsp;Michelle Ho,&nbsp;Alfredo Perales-Puchalt,&nbsp;Makan Khoshnejad,&nbsp;J Joseph Kim,&nbsp;Laurent Humeau,&nbsp;Alagarsamy Srinivasan,&nbsp;David B Weiner,&nbsp;Kar Muthumani","doi":"10.18632/genesandcancer.214","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is a prevalent cancer in men and consists of both indolent and aggressive phenotypes. While active surveillance is recommended for the former, current treatments for the latter include surgery, radiation, chemo and hormonal therapy. It has been observed that the recurrence in the treated patients is high and results in castration resistant prostate cancer for which treatment options are limited. This scenario has prompted us to consider immunotherapy with synthetic DNA vaccines, as this approach can generate antigen-specific tumor-killing immune cells. Given the multifocal and heterogeneous nature of prostate cancer, we hypothesized that synthetic DNA vaccines targeting different prostate specific antigens are likely to induce broader and improved immunity who are at high risk as well as advanced clinical stage of prostate cancer, compared to a single antigen approach. Utilizing a bioinformatics approach, synthetic enhanced DNA vaccine (SEV) constructs were generated against STEAP1, PAP, PARM1, PSCA, PCTA and PSP94. Synthetic enhanced vaccines for prostate cancer antigens were shown to elicit antigen-specific immune responses in mice and the anti-tumor activity was evident in a prostate tumor challenge mouse model. These studies support further evaluation of the DNA tools for immunotherapy of prostate cancer and perhaps other cancers.</p>","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":"12 ","pages":"51-64"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045963/pdf/","citationCount":"5","resultStr":"{\"title\":\"Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.\",\"authors\":\"Devivasha Bordoloi,&nbsp;Peng Xiao,&nbsp;Hyeree Choi,&nbsp;Michelle Ho,&nbsp;Alfredo Perales-Puchalt,&nbsp;Makan Khoshnejad,&nbsp;J Joseph Kim,&nbsp;Laurent Humeau,&nbsp;Alagarsamy Srinivasan,&nbsp;David B Weiner,&nbsp;Kar Muthumani\",\"doi\":\"10.18632/genesandcancer.214\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer is a prevalent cancer in men and consists of both indolent and aggressive phenotypes. While active surveillance is recommended for the former, current treatments for the latter include surgery, radiation, chemo and hormonal therapy. It has been observed that the recurrence in the treated patients is high and results in castration resistant prostate cancer for which treatment options are limited. This scenario has prompted us to consider immunotherapy with synthetic DNA vaccines, as this approach can generate antigen-specific tumor-killing immune cells. Given the multifocal and heterogeneous nature of prostate cancer, we hypothesized that synthetic DNA vaccines targeting different prostate specific antigens are likely to induce broader and improved immunity who are at high risk as well as advanced clinical stage of prostate cancer, compared to a single antigen approach. Utilizing a bioinformatics approach, synthetic enhanced DNA vaccine (SEV) constructs were generated against STEAP1, PAP, PARM1, PSCA, PCTA and PSP94. Synthetic enhanced vaccines for prostate cancer antigens were shown to elicit antigen-specific immune responses in mice and the anti-tumor activity was evident in a prostate tumor challenge mouse model. These studies support further evaluation of the DNA tools for immunotherapy of prostate cancer and perhaps other cancers.</p>\",\"PeriodicalId\":38987,\"journal\":{\"name\":\"Genes and Cancer\",\"volume\":\"12 \",\"pages\":\"51-64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045963/pdf/\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genes and Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18632/genesandcancer.214\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genes and Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/genesandcancer.214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 5

摘要

前列腺癌是一种常见的男性癌症,由惰性和侵袭性表型组成。虽然建议对前者进行主动监测,但目前对后者的治疗包括手术、放疗、化疗和激素治疗。据观察,在接受治疗的患者中,复发率很高,导致去势抵抗性前列腺癌,治疗选择有限。这种情况促使我们考虑使用合成DNA疫苗进行免疫治疗,因为这种方法可以产生抗原特异性肿瘤杀伤免疫细胞。鉴于前列腺癌的多灶性和异质性,我们假设,与单一抗原方法相比,针对不同前列腺特异性抗原的合成DNA疫苗可能会诱导高风险和晚期前列腺癌患者更广泛和更好的免疫。利用生物信息学方法,合成了针对STEAP1、PAP、PARM1、PSCA、PCTA和PSP94的合成增强DNA疫苗(SEV)构建体。前列腺癌抗原合成增强疫苗在小鼠中引起抗原特异性免疫反应,在前列腺肿瘤攻击小鼠模型中显示出明显的抗肿瘤活性。这些研究支持进一步评估用于前列腺癌和其他癌症免疫治疗的DNA工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.

Prostate cancer is a prevalent cancer in men and consists of both indolent and aggressive phenotypes. While active surveillance is recommended for the former, current treatments for the latter include surgery, radiation, chemo and hormonal therapy. It has been observed that the recurrence in the treated patients is high and results in castration resistant prostate cancer for which treatment options are limited. This scenario has prompted us to consider immunotherapy with synthetic DNA vaccines, as this approach can generate antigen-specific tumor-killing immune cells. Given the multifocal and heterogeneous nature of prostate cancer, we hypothesized that synthetic DNA vaccines targeting different prostate specific antigens are likely to induce broader and improved immunity who are at high risk as well as advanced clinical stage of prostate cancer, compared to a single antigen approach. Utilizing a bioinformatics approach, synthetic enhanced DNA vaccine (SEV) constructs were generated against STEAP1, PAP, PARM1, PSCA, PCTA and PSP94. Synthetic enhanced vaccines for prostate cancer antigens were shown to elicit antigen-specific immune responses in mice and the anti-tumor activity was evident in a prostate tumor challenge mouse model. These studies support further evaluation of the DNA tools for immunotherapy of prostate cancer and perhaps other cancers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Genes and Cancer
Genes and Cancer Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.90
自引率
0.00%
发文量
6
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信